C hristopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last November, and immediately made a big move: a series of three acquisitions totaling $24 billion that ...

James M. Cornelius to take over position on an interim basis.Hoping to start clean up of the legal quagmire created by efforts to protect sales of the company s biggest selling drug, blood ...

Giovanni Caforio, Bristol Myers Squibb's CEO, told Insider he was confident the $144 billion company would be able to keep growing even as those drug sales faded away.

In a surprise move, Bristol-Myers Squibb announced that it will acquire Celgene for $74 billion in stock and cash – roughly a 54% premium. Bristol CEO, Giovanni Caforio justified the acquisition ...

BOSTON (MarketWatch) -- Bristol-Myers Squibb Co., under pressure from a court-appointed overseer, on Tuesday fired Chief Executive Peter Dolan just weeks after a deal he brokered to keep a generic ...

Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's slew of recent acquisitions in a Monday interview with CNBC's Jim Cramer. Boerner highlighted his company's deal with ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia, saying the treatment is effective without the ...

Bristol Myers Squibb CEO warns against “slashing U.S. investment in medicines or importing lackluster policies of less innovative health care systems.” ...

SAN FRANCISCO (MarketWatch) -- Bristol-Myers Squibb said late Tuesday Lamberto Andreotti, the drug maker's president and chief operating officer, has been promoted to succeed Chief Executive James ...

Bristol-Myers Squibb Co.'s board has elected Chief Executive James M. Cornelius as chairman. His current contract, which had 15 months left on it, has been terminated.  ...